| Identification | Back Directory | [Name]
MSA-2 | [CAS]
129425-81-6 | [Synonyms]
MSA-2
Benzo[b]thiophene-2-butanoic acid, 5,6-dimethoxy-γ-oxo- | [Molecular Formula]
C14H14O5S | [MDL Number]
MFCD32640674 | [MOL File]
129425-81-6.mol | [Molecular Weight]
294.32 |
| Chemical Properties | Back Directory | [Boiling point ]
509.3±50.0 °C(Predicted) | [density ]
1.336±0.06 g/cm3(Predicted) | [storage temp. ]
4°C, protect from light | [solubility ]
DMSO: 125 mg/mL (424.71 mM) | [form ]
A crystalline solid | [pka]
4.35±0.17(Predicted) | [color ]
Light yellow to brown |
| Hazard Information | Back Directory | [Description]
MSA-2 was identified in a phenotypic screen for a chemical inducer of interferon beta secretion. In cell-free assays, MSA-2 binds to human and mouse STING. In tumor-bearing mice, MSA-2 induced elevated interferon-beta in plasma and tumors through two routes of administration. | [Uses]
MSA-2 is an oral non-nucleotide STING agonist with EC50 of 8.3 and 24 μM for human STING isoforms WT and HAQ, respectively. | [in vivo]
MSA-2 dosed via either PO or SC regimens achieved comparable exposure in both tumor and plasma. MSA-2 also exhibits dose-dependent antitumor activity when administered by IT, SC, or PO routes, and dosing regimens were identified that induced complete tumor regressions in 80 to 100% of treated animals[1].
MSA-2 (PO: 60 mg/kg or SC: 50 mg/kg; single dose) that effectively inhibits tumor growth induced substantial elevations of IFN-β, interleukin-6 (IL-6), and TNF-α in tumor[1]. | Animal Model: | MC38 tumor-bearing C57BL6 mice[1] | | Dosage: | 60 mg/kg | | Administration: | P.o. ; s.c (50 mg/kg); single dose | | Result: | PO or SC doses of MSA-2 that effectively inhibited tumor growth induced substantial elevations of IFN-β, interleukin-6 (IL-6), and TNF-α in tumor.
|
| [storage]
Store at -20°C |
|
|